3. Farmer barely references INFI's candidate as a competitor (as iwfal posted, he notes that the drug is basically 17AAG once in the bloodstream
I know this is a little off topic, but can someone give a legitimate point as to why INFI has gone from 6 to 13 (still only 350 mill mkt cap) after failing their Hh trial in pancreatic (it wasnt even close to being good), and comments that their Hsp isn't even an after-thought?